Week #40

USD/BTC = $62,937
Block 952,789

Here are the stocks I plan on buying this week:Here are the stocks I plan on buying this week:

🐂 = Bull Case
🐻 = Bear Case

Latest Updates:Latest Updates:

Cathedra is now Sphere 3D.Cathedra is now Sphere 3D.

Sphere 3D and Cathedra Bitcoin Announce Closing of Business CombinationSphere 3D and Cathedra Bitcoin Announce Closing of Business Combination

June 1, 2026June 1, 2026

Combination creates a scaled data infrastructure platform with 53megawatts of operating capacity and a 100mw+ expansion pipeline ; Combined company retains Sphere 3D’s name and US listing (NASDAQ: ANY)

TORONTO, ONTARIO, AND STAMFORD, CONNECTICUT, June 1, 2026 – (NEWSFILE) – Sphere 3D Corp. (NASDAQ: ANY) (“Sphere”) and Cathedra Bitcoin Inc. (TSX-V: CBIT; OTCQB: CBTTF) (“Cathedra” and together with Sphere, the “Parties”) today announced that they have completed the previously announced plan of arrangement (the “Transaction”) pursuant to which Sphere acquired all of the issued and outstanding shares of Cathedra under the arrangement agreement entered into on March 5, 2026 (the “Agreement”), and Cathedra is now a wholly-owned subsidiary of Sphere (Sphere, together with Cathedra and their subsidiaries following completion of the Transaction, the “Combined Company”). The Transaction was completed by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia). The Transaction was approved at a special meeting of the securityholders of Cathedra and at a meeting of the shareholders of Sphere, and by the Supreme Court of British Columbia.

“Closing this combination marks a significant milestone for both companies and our shareholders,” said Joel Block, Chief Executive Officer of the Combined Company. “We have integrated Cathedra’s energy-centric infrastructure platform with Sphere’s public-market presence and robust balance sheet to build a larger, more diversified enterprise with a clear growth trajectory. Together, we offer 53 MW of operational capacity, a pipeline exceeding 100 MW of potential expansion, and a NASDAQ-listed platform designed for scalability. We believe the Combined Company is strategically positioned to generate long-term value by seizing opportunities in high-performance computing and digital asset infrastructure.”

Fractyl HealthFractyl Health

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

BURLINGTON, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced positive one-year results from its open-label REVEAL-1 Cohort. The REVEAL-1 Cohort is an open-label study in individuals with obesity who have lost at least 15% of their total body weight on a GLP-1 medication and who either need or choose to discontinue GLP-1 therapy. The REVEAL-1 data show that patients who underwent a single Revita procedure maintained approximately 78% of their prior GLP-1-induced weight loss at one year, with 33% of patients continuing to lose weight one year after discontinuing a GLP-1. The new results highlight Revita’s potential to be a compelling procedural therapy for post-GLP-1 weight maintenance.

About Revita

Revita is Fractyl Health’s lead product candidate, designed to remodel the duodenal lining via a one-time, minimally invasive endoscopic procedure intended to restore healthy nutrient sensing and signaling disrupted by chronic metabolic disease. Revita has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for weight maintenance in people with obesity who discontinue GLP-1 therapies. Revita is for investigational use only in the United States and is CE marked in the European Union and United Kingdom.

About Fractyl Health

Fractyl Health is a clinical-stage metabolic therapeutics company advancing two differentiated candidates designed to target the root causes of obesity and T2D: Revita, a procedural therapy in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV-based gene therapy platform with its lead candidate RJVA-001 entering first-in-human clinical studies. Fractyl’s goal is to advance metabolic disease treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.

Commentary:Commentary:

Not much news to share this week. Almost skipped this week but with everything selling off on Friday I thought monday could be a missed opportunity if the bulls come back and bid everything back up. Can’t wait to see how this Sphere 3D company will work out after the merger with Cathedra. But another company joins the graveyard of INX, and BTM. At least this time my shares are zeroed out.

Until next week Stackers!